Amylin Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Other

David Geoffrey Parkes

Christine Marie Mack

Soumitra S Ghosh

Carolyn M Jodka

Michael R Hanley

Odile Esther Levy

Lawrence J D'Souza

Christopher Joseph Soares

Diana Y Lewis

Richard A Pittner

Andrew A Young

Kathryn Susan Prickett

Alain D Baron

Mary Erickson

Ved Srivastava

Samuel Janssen

Kevin D Laugero

John S Ahn

Jonathan David Roth

Sean H Adams

Thao Le

Lawrence J D'souza

Bronislava Gedulin

Qing Lin

Behrouz Bruce Forood

Krystyna Tatarkiewicz

Christian Weyer

Denis Roy

Paul McGonigle

Lawrence D'SOUZA

Soumitra G Ghosh

Diana Yvonne Lewis

Carolyn Marie Jodka

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Hybrid polypeptides with selectable properties

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

GIP analog and hybrid polypeptides with selectable properties

The present invention provides novel Pancreatic Polypeptide Family ('PPF') polypeptides and methods for their use.

Pancreatic polypeptide family motifs, polypeptides and methods comprising the same

GIP and exendin hybrid polypeptides

The present invention relates to novel Pancreatic Polypeptide Family ('PPF') polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.

Pancreatic polypeptide family motifs and polypeptides comprising the same

The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

Methods for treatment using amylin family peptides

DPP-IV resistant GIP hybrid polypeptides with selectable properties

The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.

Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis

Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.

Amylin and amylin agonists for treating psychiatric diseases and disorders

Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.

Neuromedin and FN-38 peptides for treating psychiatric diseases

Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet and nutrition are provided. The methods provided generally involve the administration of an Amylin or an Amylin agonist to a subject in order to prevent, treat or control conditions or disorders associated with obesity, diet and nutrition.

Method of modifying food preference comprising administering amylin or amylin agonist

Growing community of inventors

Del Mar, CA, United States of America

David Geoffrey Parkes